<DOC>
	<DOCNO>NCT01089790</DOCNO>
	<brief_summary>This study evaluate long-term safety efficacy dutogliptin patient type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Safety Efficacy Dutogliptin Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone Combination With Metformin With Pioglitazone Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Have successfully complete required visit qualify Phase 3 core protocol Be currently receive treatment T2DM set forth qualify Phase 3 core protocol Any condition , disease , disorder clinically relevant laboratory abnormality , opinion investigator , would jeopardize patient 's appropriate participation study obscure effect treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>